Literature DB >> 25044226

Impact of adverse left ventricular remodeling on sudden cardiac death in patients with hypertrophic cardiomyopathy.

Pieter A Vriesendorp1, Arend F L Schinkel, Natasja M S de Groot, Ron T van Domburg, Folkert J Ten Cate, Michelle Michels.   

Abstract

BACKGROUND: Adverse left ventricular (LV) remodeling predicts heart failure symptoms and overt LV dysfunction in patients with hypertrophic cardiomyopathy (HCM), but its influence on the occurrence of sudden cardiac death (SCD) is unknown. The aim of this study was to investigate the effect of adverse LV remodeling on SCD risk in patients with HCM. HYPOTHESIS: Adverse LV remodeling increases SCD in HCM patients.
METHODS: This study included 41 patients with HCM who experienced SCD; each case was matched with 3 controls based on age, gender, and time of first contact. In this population of 164 patients, predictors of SCD were identified using univariable and multivariable logistic regression and expressed as odds ratio (OR) with 95% confidence interval (CI).
RESULTS: Baseline characteristics, such as New York Heart Association (NYHA) class, systolic and diastolic left ventricular function, left ventricular wall thickness, left atrial size, atrial fibrillation, and established risk factors for SCD were similar in cases and controls. Independent predictors of SCD during follow-up (median follow-up, 7.7 ± 6.5 years) were: increase in NYHA class (OR: 8.7 [95% CI: 2.5-30.5], P = 0.001), decrease of fractional shortening (per % decrease, OR: 1.09 [95% CI: 1.03-1.14], P = 0.001), and decrease of diastolic function (OR: 3.5 [95% CI: 1.2-10.2], P = 0.02).
CONCLUSIONS: This study shows that SCD risk in HCM increases when adverse remodeling occurs. Because cases and controls were similar at baseline, these findings emphasize the importance of vigilant follow-up of HCM patients and could aid clinical decision making concerning implantable cardioverter-defibrillator implantation, especially in patients with moderate risk for SCD.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25044226      PMCID: PMC6649612          DOI: 10.1002/clc.22293

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

1.  Clinical Characteristics and Prognosis of End-stage Hypertrophic Cardiomyopathy.

Authors:  Yan Xiao; Kun-Qi Yang; Yan-Kun Yang; Ya-Xin Liu; Tao Tian; Lei Song; Xiong-Jing Jiang; Xian-Liang Zhou
Journal:  Chin Med J (Engl)       Date:  2015-06-05       Impact factor: 2.628

2.  Living with hypertrophic cardiomyopathy and an implantable defibrillator.

Authors:  Peter Magnusson; Jessica Jonsson; Stellan Mörner; Lennart Fredriksson
Journal:  BMC Cardiovasc Disord       Date:  2017-05-10       Impact factor: 2.298

3.  Life-long tailoring of management for patients with hypertrophic cardiomyopathy : Awareness and decision-making in changing scenarios.

Authors:  M Michels; I Olivotto; F W Asselbergs; J van der Velden
Journal:  Neth Heart J       Date:  2017-03       Impact factor: 2.380

4.  Rosmarinic acid attenuates cardiac fibrosis following long-term pressure overload via AMPKα/Smad3 signaling.

Authors:  Xin Zhang; Zhen-Guo Ma; Yu-Pei Yuan; Si-Chi Xu; Wen-Ying Wei; Peng Song; Chun-Yan Kong; Wei Deng; Qi-Zhu Tang
Journal:  Cell Death Dis       Date:  2018-01-24       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.